

1 - 8 - 02Attorney Docket No.: V0139/7050

UTILITY PATENT APPLICATION **TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

Attomey Docket No.	V0139/7050	õ	- So-
First Named Inventor or Application Identifier		7.70	10/1
WARD, Gary E.		, u.,	

EL844452859US

November 9, 2001

Box Patent Application ADDRESS Commissioner for Patents TO: Washington, DC 20231 CD-ROM or CD-R, in duplicate, large table or 8. 🗆 Computer Program (Appendix)

(Submit an original, and a duplicate for fee processing)	Computer Program (Appendix)			
Applicant claims small entity status. See 37 CFR 1.27.	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. ⊠ Computer Readable Form (CRF)			
 Statement filed in prior application, status still proper and desired. 	a. ⊠ Computer Readable Form (CRF) b. ⊠ Specification Sequence Listing on: i.□ CD-ROM or CD-R (2 copies); or			
3. ⊠Specification -Total pages	ii. ⊠ paper (identical to computer copy) c. ⊠ Statement verifying identity of above copies			
39 - pages description1 - pages abstract	ACCOMPANYING APPLICATION PARTS			
4 - pages claims 37 - Total claims 4. □ Drawing(s) (35 USC 113) - Total sheets	10. ☐ Assignment Papers/cover sheet & documents(s)			
☐ Informal ☐ Formal - Total drawings 5. ☐ Oath or Declaration - Total pages	11. □ 37 CFR 3.73(b) Statement (when there is an assignee) □ Power of Attorney			
 a. Newly executed (original or copy) b. Copy from a prior application (37 CFR 1 63(d)) (for continuation/divisional with Box 18 completed) 	12. □ English Translation of Document (if applicable)			
[Note Box 6 below]	13. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations			
 i. □ DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 	14. □ Preliminary Amendment			
6. ☐ Incorporation by Reference	15. ☑ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)			
(usable if Box 5b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being	16. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)			
part of the disclosure of the accompanying application and is hereby incorporated by reference therein. See 19.	17. ⊠ Request and Certification Under 35 U.S.C. §122(b)(2)(B)(ii)			
	18. Other:			
7. ⊠ Application Data Sheet, See 37 CFR 1.76				

Express Mail Label No.

Date of Deposit

19. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in the body of the application, or a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:								
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:, filed on, entitled and now								
☐ Cancel in this application claims before calculating the filing fee.								
☐ Amend the specification by inserting before the first line of the specification on page 1, after the title, the following: This application is a ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:, filed on, entitled and now								
Prior application information: Examiner Group Art Unit:								
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.								
	20.	CORRESE	PONDENCE AD	DRESS				
Correspondence address	below							
CUSTOMER NUMBER: 23628								
OR								
ATTORNEY'S NAME	Helen C. Lockhart, Reg. No. 39,248							
FIRM NAME	Wolf, Greenfield & Sacks, P.C.							
ADDRESS	600 Atlantic Avenue							
CITY	Boston	· · · · · ·	STATE	MA	ZIP	02210		
COUNTRY	USA		TELEPHONE	(617) 720-3500	FAX	(617) 720-2441		
20. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED								
NAME		Helen C. Lockhart, Reg. No. 39,248						
SIGNATURE		Helle hoelfant						
DATE	November 9, 2001							

Express Mail Label No. EL844452859US Date of Deposit: November 9, 2001

Attorney Docket No: V0139/7050(HCL)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Serial No.:

Gary E. Ward et al. Not Yet Assigned

Filed:

Herewith

For:

TOXOPLASMA GONDII APICAL MEMBRANE ANTIGEN-1

Examiner:

Unassigned

Art Unit:

Unknown

Box Patent Application Commissioner for Patents Washington, D.C. 20231

STATEMENT PURSUANT TO 37 CFR 1.821(f)

Sir:

This statement is made pursuant to 37 CFR 1.821(f). Applicants enclose herewith a copy of the Sequence Listing and a computer readable diskette. Applicants' attorney states that the content of the paper copy of the Sequence Listing and the computer readable diskette contain the identical information.

Respectfully submitted,

Helen C. Lockhart Reg. No. 39,248

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue Boston, MA 02210-2211

Docket No. V0139/7050(HCL) (617)720-3500

Date: November 9, 2001

X11/09/01

REQUEST AND CERTIFICATION UNDER 35 U.S.C. 122(b)(2)(B)(ii)

First Named Inventor WARD, Gary E.

Title TOXOPLASMA GONPII APICAL
MEMBRANE ANTIGEN-1

Attorney Docket No. V0139/7050

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

November 9, 2001 Date

Signatur

Helen C. Lockhart

Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**